JPRN-jRCT2080223265已完成3 期
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Intravenous MR11A8 in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Japanese patient has a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS
- •a) Acute onset of respiratory failure within 1 week of a known clinical insult or new or worsening respiratory symptoms
- •b) Respiratory failure associated with known ARDS risk factors and not fully explained by either cardiac failure or fluid overload (an objective assessment of cardiac failure or fluid overload is needed if no risk factors for ARDS are present)
- •c) Radiological abnormalities on chest X-ray or on computerised tomography scan, i.e., bilateral opacities that are not fully explained by effusions, nodules, masses or lobar/lung collapse
- •d) Hypoxaemia
- •Moderate ARDS 100mmHg=5cmH2O
- •Severe ARDS PaO2/FiO2<=100mmHg with positive end expiratory pressure PEEP>=5cmH2O
- •(2) The radiological and hypoxaemia criteria in ARDS criteria (c and d) must be met within the same 24-hour period. The time of onset of ARDS is when the last of the two specified ARDS criteria is met
- •(3) Administration of the first dose of study drug must be planned to take place within 48 hours of first fulfilling the above inclusion criteria
- •(4) Patient is intubated and mechanically ventilated
- •(5) A signed informed consent form from the patient or the patients personal legal representative or a professional legal representative must be available
排除标准
- •(1) Woman known to be pregnant, lactating or with a positive or indeterminate pregnancy test
- •(2) Patient is simultaneously taking part in another pharmacotherapy protocol
- •(3) The patient is not expected to survive for 24 hours
- •(4) Patient has an underlying clinical condition where, in the opinion of the Investigator, it would be extremely unlikely that the patient would come off ventilation, e.g., motor neuron disease, Duchenne muscular dystrophy or rapidly progressive interstitial pulmonary fibrosis
- •(5) Patient has severe chronic obstructive pulmonary disease requiring long-term home oxygen therapy or mechanical ventilation (non-invasive ventilation or via tracheotomy) except for continuous positive airway pressure (CPAP) or bi-level positive airway pressure used solely for sleep-disordered breathing
- •(6) Patient has congestive heart failure, defined as New York Heart Association class 4
- •(7) Patient has acute left ventricular failure
- •(8) Patient has liver failure (Child-Pugh grade C)
- •(9) Patient has received any prior interferon (IFN)
- •(10) Patient has known hypersensitivity to natural or recombinant IFN beta or to any of the excipients
- •(11) Patient is receiving renal dialysis therapy for chronic renal failure
- •(12) Patient is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extracorporeal lung support
- •(13) Patient has had any form of mechanical ventilation (invasive or non-invasive, excluding CPAP alone) for longer than 48 hours prior to the diagnosis of ARDS. Non-invasive ventilation has to be continuously applied for at least 12 hours per day in these 48 hours
- •(14) Patient has burns to >_15% of their total body surface area
- •(15) Patient is receiving Sho-saiko-to or is scheduled to receive Sho-saiko-to during the study drug administration period
研究者
相似试验
进行中（未招募）
1 期
MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participantsTreatment of hepatitis C virus (HCV) infectionMedDRA version: 20.0 Level: LLT Classification code 10019752 Term: Hepatitis C virus (HCV) System Organ Class: 100000074171EUCTR2017-001463-21-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.426
进行中（未招募）
1 期
MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participantsTreatment of hepatitis C virus (HCV) infectionMedDRA version: 20.0 Level: LLT Classification code 10019752 Term: Hepatitis C virus (HCV) System Organ Class: 100000004848EUCTR2017-001463-21-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.426
进行中（未招募）
1 期
MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participantsTreatment of hepatitis C virus (HCV) infectionMedDRA version: 20.0Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 100000074171EUCTR2017-001463-21-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.426
进行中（未招募）
1 期
MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participantsEUCTR2017-001463-21-LTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.426
进行中（未招募）
1 期
MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participantsEUCTR2017-001463-21-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.426